50.46
price down icon3.61%   -1.89
after-market After Hours: 51.08 0.62 +1.23%
loading
Moonlake Immunotherapeutics stock is traded at $50.46, with a volume of 1.18M. It is down -3.61% in the last 24 hours and up +6.91% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$52.35
Open:
$52.46
24h Volume:
1.18M
Relative Volume:
2.27
Market Cap:
$3.20B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-21.94
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
-9.47%
1M Performance:
+6.91%
6M Performance:
+7.09%
1Y Performance:
+22.30%
1-Day Range:
Value
$46.12
$52.57
1-Week Range:
Value
$46.12
$56.58
52-Week Range:
Value
$31.42
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Name
Moonlake Immunotherapeutics
Name
Phone
41 41 510 8022
Name
Address
DORFSTRASSE 29, ZUG
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
50.46 3.32B 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-19-25 Upgrade Wolfe Research Peer Perform → Outperform
Mar-18-25 Initiated RBC Capital Mkts Outperform
Jan-17-25 Upgrade Goldman Neutral → Buy
Nov-05-24 Resumed Wedbush Outperform
Aug-26-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-25-24 Initiated Oppenheimer Outperform
Apr-02-24 Initiated Goldman Neutral
Feb-15-24 Initiated Wolfe Research Outperform
Dec-08-23 Initiated Citigroup Buy
Nov-02-23 Initiated Stifel Buy
Sep-14-23 Downgrade Bryan Garnier Buy → Neutral
Aug-31-23 Initiated Needham Buy
Jun-15-23 Initiated Barclays Equal Weight
May-01-23 Initiated Guggenheim Buy
Mar-22-23 Initiated Wedbush Outperform
Mar-09-23 Initiated BTIG Research Buy
Feb-14-23 Initiated Cantor Fitzgerald Overweight
Feb-02-23 Initiated Bryan Garnier Buy
Nov-11-22 Initiated Jefferies Buy
Aug-25-22 Initiated SVB Leerink Outperform
Jul-21-22 Initiated H.C. Wainwright Buy
Jul-07-22 Initiated Cowen Outperform
View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

pulisher
01:04 AM

MoonLake Immunotherapeutics Inches Toward Key Resistance — Will It BreakEntry Plan for Oversold Reversal Stocks Released - metal.it

01:04 AM
pulisher
Jul 29, 2025

Is Now a Good Time to Reenter MoonLake ImmunotherapeuticsSwing Trade Entry With Volume Triggers Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 20:29:47 - beatles.ru

Jul 29, 2025
pulisher
Jul 29, 2025

Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

What does MLTX's flat EPS in 2024 suggest for investors? - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

Does MoonLake Immunotherapeutics stock perform well during market downturnsStock Market Data Feed For Consistent Profits - jammulinksnews.com

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 08:56:36 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayWealth Building Stock Market Ideas Based on Momentum - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 07:59:51 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 06:35:51 - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What institutional investors are buying MoonLake Immunotherapeutics stockFast-track wealth growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Is MoonLake Immunotherapeutics stock overvalued or undervaluedTake advantage of unprecedented market momentum - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does MoonLake Immunotherapeutics generate profit in a changing economyFree Stock Market Trend Analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How strong is MoonLake Immunotherapeutics company’s balance sheetAchieve explosive financial results today - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

How does MoonLake Immunotherapeutics compare to its industry peersInvest smarter with advanced market data - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive MoonLake Immunotherapeutics stock higher in 2025Invest confidently with professional advice - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are MoonLake Immunotherapeutics company’s key revenue driversBuild a diversified portfolio for stability - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Does MoonLake Immunotherapeutics (NASDAQ:MLTX) Have A Healthy Balance Sheet? - 富途牛牛

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about MoonLake Immunotherapeutics stockMarket-leading profit generation - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

MoonLake Immunotherapeutics Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 23, 2025

Is MoonLake Immunotherapeutics a good long term investmentBreakthrough stock performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com

Jul 22, 2025

Moonlake Immunotherapeutics Stock (MLTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Moonlake Immunotherapeutics Stock (MLTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Moukheibir Catherine
Director
Jul 03 '25
Sale
48.79
23,500
1,146,565
0
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Cap:     |  Volume (24h):